ClinicalTrials.gg
RecruitingNCT07381660Updated Sep 1, 2026

SBRT Versus Surgical Resection for Small HCC

A Phase 3 interventional study of Stereotactic body radiotherapy (SBRT) and Resection in Hepatocellular Carcinoma (HCC), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University — 58 open to participants now, 65 under way, 10 of them phase 3. Carcinoma, Hepatocellular · Sun Yat-sen University.

Planned enrollment
12th of 161
390 · median 120
Started
2026
with 5 others
Phase 3
51 of 187
8 open now
Primary completion
2031-12
later than 63 of 64 live
Registered
183rd of 187
by date

Among the 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University, this one is the 12th largest by planned enrollment of the 161 interventional ones that give a count, is one of 6 that started in 2026, is one of 51 in phase 3, reaches primary completion later than 63 of the 64 other live ones, and was the 183rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

58 of the 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 58 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University, or all of them as a file.
02

Study summary

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related incidence and mortality in China and represents a major public health challenge. Surgical resection is the most commonly used curative treatment for HCC and can provide favorable long-term outcomes. However, resection is associated with substantial perioperative morbidity, and its applicability is limited in certain patient populations, including those with recurrent disease, those who have undergone conversion therapy, and those with significant coexisting medical conditions.

Advances in radiotherapy technology and the development of highly precise delivery techniques have led to the increasing use of stereotactic body radiotherapy (SBRT) in the management of HCC, particularly in patients with small tumors. Randomized controlled trials conducted by our group have shown that, in patients with recurrent small HCC, SBRT provides superior local tumor control compared with radiofrequency ablation. These findings suggest that SBRT may represent a potentially curative treatment option for selected patients with small HCC.

On the basis of this evidence, the present study is designed to compare the efficacy and safety of surgical resection and SBRT in patients with small HCC. Patients with a solitary tumor measuring 5 cm or less in maximum diameter will be randomly assigned to undergo either surgical resection or SBRT. The primary end point of the study is overall survival. This trial aims to define the relative benefits and risks of these two treatment strategies and to provide high-quality evidence to inform clinical decision making and future guideline recommendations.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
  • SBRT
  • Resection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years, with no restriction on sex;
  2. Clinically or diagnosed hepatocellular carcinoma, according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 edition);
  3. A solitary tumor with a maximum diameter of ≤5 cm, for which treatment is indicated;
  4. No radiologic evidence of macrovascular invasion, distant , or lymph node metastasis;
  5. Treatment-naïve or previously treated patients are eligible, provided that they are deemed suitable for both surgical resection and radiotherapy by a multidisciplinary team (MDT) and do not require concomitant systemic therapy at enrollment;
  6. For patients with recurrent disease, recurrence must occur at least 1 year after prior curative treatments;
  7. Previously treated patients must not have received systemic therapy within 6 months before enrollment;
  8. In previously treated patients, tumor size must be assessed according to version 1.1 at enrollment;
  9. A normal liver volume of ≥700 cc, with an estimated future liver remnant volume of >40% after resection;
  10. A performance-status score of ≥90;
  11. class A liver function;
  12. An estimated of more than 6 months;
  13. Adequate organ function, defined as follows: white-cell count ≥3.5×10⁹/L, ≥1.5×10⁹/L, count ≥75.0×10⁹/L, ≥90 g/L; serum albumin ≥28 g/L; total ≤1.5 times the (ULN), or aspartate aminotransferase ≤2.5 times the ULN; serum creatinine ≤1.5 times the ULN or >60 mL per minute; and no severe concomitant organic disease;
  14. The ability to understand the study procedures and to provide written before the initiation of any study-specific procedures, with agreement to receive treatment and follow-up according to the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Severe dysfunction of major organs, including the heart, lungs, or kidneys; active infection other than viral hepatitis; or other serious concomitant conditions that preclude tolerance of either surgery or radiotherapy;
  2. to surgical resection or radiotherapy;
  3. A history of other malignant tumors, with the exception of nonmelanoma skin cancer, carcinoma in situ of the cervix, or previously cured prostate cancer, nasopharyngeal carcinoma, breast cancer, or early-stage laryngeal cancer;
  4. A history of multiple abdominal surgeries or liver or other solid-organ transplantation;
  5. Previous radiotherapy to the upper abdomen;
  6. Pregnancy or breastfeeding;
  7. Any other condition that may interfere with patient enrollment or the assessment of study outcomes;
  8. Refusal to comply with the follow-up requirements of the study protocol or refusal to provide written .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • Active comparator
    Resection

    Patient receive surgical resection

    Procedure: Resection

  • Experimental
    SBRT

    Patient receive SBRT

    Radiation: Stereotactic body radiotherapy (SBRT)

Interventions

  • RadiationStereotactic body radiotherapy (SBRT)

    The SBRT dose ranges from 33 to 54 Gy and is delivered in three fractions on alternate days, with treatment completed within one week. This study enrolls patients with small hepatocellular carcinoma, defined as a solitary tumor with a maximum diameter of ≤5 cm, and compares the efficacy of SBRT with that of surgical resection.

  • ProcedureResection

    Surgical resection serves as the control treatment in this study

06

What researchers measure

Primary outcomes

  1. OS

    time from random assignment to death from any cause

    Time frame: time from random assignment to death from any cause, assessed up to 100 months

Secondary outcomes

  1. PFS

    time from random assignment to tumor progression or death fromany cause

    Time frame: time from random assignment to tumor progression or death fromany cause, assessed up to 100 months

  2. LPFS

    time from random assignment to local tumor progression or death fromany cause

    Time frame: time from random assignment to local tumor progression or death fromany cause, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD are available from the corresponding author (Minshan Chen and Yaojun Zhang) by request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months and ending 2 years after the publication of results

Access criteria: For academic discussion purposes, investigators who are interested in this study may contact the study team by email to request the study protocol, the statistical analysis plan, and other relevant materials.

Data sharing details ↗ · www.researchdata.org.cn

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2031, 69 months after the start.

Of 86 non-industry phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 109. This study's planned 69 months is close to that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Feb 2, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07381660
Responsible party
Chen Min-Shan (Professor, Sun Yat-sen University) — Principal investigator
First posted
Feb 2, 2026
Start date
Mar 18, 2026
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 1, 2026

Study contacts

Minshan Chen, PhD, MD
Contact
chenmsh@sysucc.org.cn
+86 13902241061
Yaojun Zhang, PhD, MD
Contact
zhangyuj@sysucc.org.cn

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion